Beam Therapeutics (BEAM) Gains from Investment Securities (2024 - 2026)
Beam Therapeutics' (BEAM) quarterly Gains from Investment Securities came in at -$514000.0 in Q1 2026, down 2003.7% year-on-year from $27000.0 in Q1 2025, and down 167.19% on a QoQ basis from $765000.0 in Q4 2025.
Beam Therapeutics (BEAM) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 3 years of Gains from Investment Securities data on file, last reported at -$514000.0 in Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 2003.7% year-over-year to -$514000.0 in Q1 2026; TTM through Mar 2026 was -$721000.0, a 57.54% increase from a year earlier, with the FY2025 full-year figure at -$180000.0, up 88.69% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$514000.0, down from $765000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for BEAM reached as high as $765000.0 in Q4 2025 and fell as low as -$1.8 million in Q2 2024.
- Historically, Gains from Investment Securities has averaged -$254000.0 across 3 years, with a median of $27000.0 in 2024.
- On a YoY basis, Gains from Investment Securities climbed as much as 2733.33% in 2025 and fell as far as 3803.7% in 2025.
- Year by year, Gains from Investment Securities stood at $27000.0 in 2024, then surged by 2733.33% to $765000.0 in 2025, then tumbled by 167.19% to -$514000.0 in 2026.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$514000.0 in Q1 2026, $765000.0 in Q4 2025, and -$1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Beam Therapeutics | 2.59 Bn | 2.59 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -514,000.00 |
| Mar 31, 2026 | -514,000.00 |
| Dec 31, 2025 | 765,000.00 |
| Dec 31, 2025 | 765,000.00 |
| Sep 30, 2025 | -1.00 Mn |
| Sep 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | 133,000.00 |
| Mar 31, 2024 | 133,000.00 |